First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Autor: Linda M. Liau, Keyoumars Ashkan, David D. Tran, Jian L. Campian, John E. Trusheim, Charles S. Cobbs, Jason A. Heth, Michael Salacz, Sarah Taylor, Stacy D. D’Andre, Fabio M. Iwamoto, Edward J. Dropcho, Yaron A. Moshel, Kevin A. Walter, Clement P. Pillainayagam, Robert Aiken, Rekha Chaudhary, Samuel A. Goldlust, Daniela A. Bota, Paul Duic, Jai Grewal, Heinrich Elinzano, Steven A. Toms, Kevin O. Lillehei, Tom Mikkelsen, Tobias Walbert, Steven R. Abram, Andrew J. Brenner, Steven Brem, Matthew G. Ewend, Simon Khagi, Jana Portnow, Lyndon J. Kim, William G. Loudon, Reid C. Thompson, David E. Avigan, Karen L. Fink, Francois J. Geoffroy, Scott Lindhorst, Jose Lutzky, Andrew E. Sloan, Gabriele Schackert, Dietmar Krex, Hans-Jorg Meisel, Julian Wu, Raphael P. Davis, Christopher Duma, Arnold B. Etame, David Mathieu, Santosh Kesari, David Piccioni, Manfred Westphal, David S. Baskin, Pamela Z. New, Michel Lacroix, Sven-Axel May, Timothy J. Pluard, Victor Tse, Richard M. Green, John L. Villano, Michael Pearlman, Kevin Petrecca, Michael Schulder, Lynne P. Taylor, Anthony E. Maida, Robert M. Prins, Timothy F. Cloughesy, Paul Mulholland, Marnix L. Bosch

Publikováno v: Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-9 (2018)

Abstract Background Standard therapy for glioblastoma includes surgery, radiotherapy, and temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax®-L) to standard therapy for newly di

Externí odkaz: https://doaj.org/article/7b4a8b2c7d344b0e9344d197a7338b0a

Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Autor: Samuel Goldlust, Tom Mikkelsen, Reid C. Thompson, David Avigan, John E. Trusheim, Marnix L. Bosch, Kevin Petrecca, David S. Baskin, David Mathieu, Sarah A. Taylor, Timothy F. Cloughesy, Jian Campian, Raphael P. Davis, Christopher Duma, Lyndon Kim, Robert M. Prins, Kevin A. Walter, Keyoumars Ashkan, Scott Lindhorst, Tobias Walbert, Andrew E. Sloan, John L. Villano, Daniela A. Bota, Simon Khagi, Santosh Kesari, David Piccioni, Michael Salacz, Manfred Westphal, Steven A. Toms, Jose Lutzky, Dietmar Krex, Linda M. Liau, Timothy J. Pluard, Paul Duic, Richard M. Green, Rekha Chaudhary, Clement Pillainayagam, Andrew Brenner, Fabio M. Iwamoto, Steven Brem, Heinrich Elinzano, Edward J. Dropcho, Karen Fink, Hans Jorg Meisel, Michael Pearlman, Michel Lacroix, Jason Heth, Julian Wu, Lynne Taylor, Kevin O. Lillehei, Stacy D. D’Andre, Pamela Z. New, Gabriele Schackert, Arnold B. Etame, David Tran, Steven R. Abram, Jai Grewal, Paul Mulholland, William G. Loudon, Sven Axel May, Francois J. Geoffroy, Victor Tse, Robert Aiken, Matthew G. Ewend, Anthony E. Maida, Michael Schulder, Jana Portnow, Charles S. Cobbs, Yaron A. Moshel

Publikováno v: Liau, Linda M; Ashkan, Keyoumars; Tran, David D; Campian, Jian L; Trusheim, John E; Cobbs, Charles S; et al.(2018). Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.. Journal of translational medicine, 16(1), 179. doi: 10.1186/s12967-018-1552-1. UC Office of the President: Research Grants Program Office (RGPO). Retrieved from: http://www.escholarship.org/uc/item/1k3480p0
Journal of Translational Medicine
Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-2 (2018)

Background Standard therapy for glioblastoma includes surgery, radiotherapy, and temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax®-L) to standard therapy for newly diagnosed g

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c249b32746a18134ef143a85ab82d24
http://www.escholarship.org/uc/item/1k3480p0